1 Caffeinated or decaffeinated coffee consumption and risk of cancer

2 incidence: meta-analyses of prospective cohort studies

- 3
- 4 Thanh N. Nguyen¹, Olga S. Cherepakhin¹, Devin K. Eng², Masaoki Kawasumi^{3,*}
- 5
- ⁶ ¹School of Medicine, University of Washington, Seattle, Washington, USA
- 7 ²College of Engineering, University of Washington, Seattle, Washington, USA
- 8 ³Division of Dermatology, Department of Medicine, University of Washington, Seattle,
- 9 Washington, USA
- 10
- 11 *Correspondence should be addressed to M.K. (kawasumi@uw.edu)
- 12
- 13

14 **Contact information**

- 15 Masaoki Kawasumi, M.D., Ph.D.
- 16 Division of Dermatology, Department of Medicine, University of Washington
- 17 850 Republican Street, Brotman Building, Room D254, Seattle, WA 98109, USA
- 18 Phone: 206-897-5456; Fax: 206-897-5442; Email: kawasumi@uw.edu
- 19

20 Abstract

21

22 Many epidemiological studies have investigated the association between coffee consumption and 23 risks for various types of cancer, yet results are conflicting. To determine the impact of coffee 24 consumption on cancer incidence, we systematically reviewed high-quality prospective cohort 25 studies for 10 major cancer types and performed meta-analyses of 63 studies from different 26 countries. For each cancer type, we calculated summary relative risks using the DerSimonian-27 Laird random-effects model and assessed dose-response relationships. Our meta-analyses 28 found that caffeinated coffee consumption, but not decaffeinated coffee, prevented liver and skin 29 cancers, highlighting the significant role of caffeine in cancer prevention. Furthermore, both 30 caffeinated and decaffeinated coffee prevented endometrial cancer, indicating the role of other 31 active compounds in coffee. Collectively, our meta-analyses revealed that coffee consumption, 32 particularly caffeinated coffee, prevents the incidence of liver, endometrial, and skin cancers in a 33 dose-dependent manner, suggesting that coffee consumption has a large impact on public health.

35 Introduction

36

37 Cancer is the second leading cause of death in the United States¹. In 2023, 1,958,310 new cancer 38 cases and 609,820 cancer deaths are projected to occur in the United States¹. Thus, cancer has 39 a significant impact on public health, and sustainable cancer prevention strategies are needed. 40 Some strategies include avoiding risk factors such as smoking and increasing the consumption 41 of fruits and vegetables². Therefore, identifying which foods and drinks prevent cancer is of great 42 importance.

43

44 Coffee is a commonly consumed beverage. In the United States, 49% of adults drink coffee every day³. Strikingly, coffee consumption reduces the risk of developing some diseases, including 45 cancer, type 2 diabetes mellitus, and hepatic fibrosis⁴⁻⁶. In a large prospective study, coffee 46 47 consumption was inversely associated with total and cause-specific mortality, showing health 48 benefits of coffee consumption⁷. Coffee contains many bioactive compounds that affect the 49 human body, such as caffeine, chlorogenic acid, diterpenes, and trigonelline⁸. Among these, caffeine has been shown to prevent UV-induced skin carcinogenesis in mouse models^{9,10}. Human 50 51 epidemiological studies also showed that daily consumption of caffeinated coffee, but not 52 decaffeinated coffee, was inversely associated with skin cancer (nonmelanoma skin cancer and 53 melanoma)¹¹⁻¹³. There are more than 100 types of cancer, which behave differently, and the effect 54 of coffee on cancer prevention may differ among these cancer types. Thus, it is important to 55 comprehensively investigate the preventive effects of caffeinated and decaffeinated coffee on 56 different cancer types.

57

58 More than 500 studies have been conducted in different countries to investigate the association 59 between coffee consumption and risks for various types of cancer⁴, yet results are conflicting

among different cancer types. Caffeinated coffee consumption prevents skin cancer¹¹⁻¹³, whereas 60 61 coffee consumption may increase the risk of bladder cancer⁴. Furthermore, the results from 62 independent studies on the same cancer type may be conflicting; one study showed that coffee 63 intake decreased the risk of ovarian cancer¹⁴, but another study demonstrated that caffeinated coffee intake increased the risk of ovarian cancer¹⁵. To better understand the impact of coffee on 64 65 human cancer incidence, high-quality human studies are needed. Among multiple types of 66 observational studies without any interventions, prospective cohort studies provide the strongest 67 scientific evidence by identifying exposure before the outcome, collecting specific exposure data, and assessing causality¹⁶. Here, we systematically reviewed prospective cohort studies on major 68 69 cancer types and performed meta-analyses of 63 studies to quantitatively synthesize the results 70 of multiple independent studies. This allows us to more precisely determine the effects of coffee 71 consumption on cancer incidence than the results derived from individual studies. To elucidate 72 the impact of caffeine, we analyzed the effects of caffeinated and decaffeinated coffee separately. 73 We also assessed whether the effect of coffee on cancer incidence differs between men and 74 women and whether it is dose dependent. Given the fact that coffee is widely consumed and 75 cancer is a common disease, the effect of coffee consumption on cancer incidence could have a 76 large impact on public health.

78 **Results**

79

80 Study selection and characteristics

81 Through our initial literature search using PubMed. Scopus, and Embase, we found 980 potential 82 articles on coffee consumption and cancer risk (Supplementary Fig. 1a). Additionally, 113 83 articles were found by reviewing reference lists from the initially selected articles and using the 84 "Similar articles" function in PubMed. After uploading these articles to Rayyan QCRI system, 85 duplicates were removed with 861 articles remaining. The initial screening selected only full-text 86 articles, which were then assessed for inclusion criteria. Subsequently, the quality of 74 remaining 87 articles was assessed using the Newcastle-Ottawa Scale (NOS) for nonrandomized studies in 88 meta-analyses, removing seven studies whose NOS scores were lower than 5. After data 89 extraction, we further eliminated four studies from our analysis because the data reported in these 90 four studies were not compatible with other studies for meta-analyses (i.e., the lowest coffee 91 consumption category was not used as reference; the number of cases in the lowest coffee 92 consumption category was less than 10; cancer subtypes were analyzed separately). As a result, 93 63 studies for 10 major cancer types were included in our meta-analyses.

94

95 The 63 prospective cohort studies included 10.068.955 people in total and were conducted in 96 different geographical regions of the world: one study from Australia, 14 from Asia (Japan and 97 Singapore), 21 from Europe (Netherlands, Sweden, Denmark, France, Germany, Greece, Italy, 98 Norway, Spain, United Kingdom, and Finland), and 27 from North America (United States and 99 Canada). The Egger's test (p = 0.0903), Begg's test (p = 0.5424), and a funnel plot of the meta-100 analysis showed no significant publication bias (Supplementary Fig. 1b). The overall summary 101 relative risk (SRR) for 10 major cancer types for high coffee consumption was 0.93 (95% 102 confidence interval [CI], 0.88–0.97) (Supplementary Fig. 2). There was high between-study

heterogeneity among included cohort studies ($l^2 = 65.7\%$, p < 0.001), which prompted us to analyze each cancer type separately.

105

106 Liver cancer (hepatocellular carcinoma)

Overall, our meta-analysis of seven prospective studies^{14,17-22} found that coffee consumption 107 108 decreased the incidence of hepatocellular carcinoma by 38% (SRR, 0.62; 95% CI, 0.52-0.75) 109 (Fig. 1a). Caffeinated coffee consumption reduced the incidence of hepatocellular carcinoma by 110 46% (SRR. 0.54: 95% CI. 0.39–0.74), whereas decaffeinated coffee consumption had a 16% 111 reduction (SRR, 0.84; 95%CI, 0.64-1.10) (Fig. 1a). A greater reduction in the incidence of 112 hepatocellular carcinoma was observed in male coffee drinkers than in female coffee drinkers: 113 44% reduction in men (SRR, 0.56; 95% CI, 0.39–0.80) and 36% reduction in women (SRR, 0.64; 114 95% CI, 0.36–1.14) (Fig. 1b). A dose-response analysis showed a noticeable decreasing trend 115 in hepatocellular carcinoma incidence with higher coffee consumption: 9.9% reduction per daily 116 cup (Fig. 1c).

117

118 Endometrial cancer

Overall, our meta-analysis of 12 prospective studies^{14,23-33} found that coffee consumption decreased endometrial cancer incidence by 30% (SRR, 0.70; 95% CI, 0.61–0.80) (**Fig. 2a**). Endometrial cancer incidence was reduced more in caffeinated coffee drinkers (SRR, 0.61; 95% CI, 0.44–0.84) than in decaffeinated coffee drinkers (SRR, 0.73; 95% CI, 0.58–0.93) (**Fig. 2a**). A dose-response analysis demonstrated a decreasing trend in endometrial cancer incidence with higher coffee consumption: 7.4% reduction per daily cup (**Fig. 2b**).

125

126 Skin cancer

Overall, our meta-analysis of seven prospective studies^{13,14,30,34-37} found that coffee consumption
decreased the incidence of skin cancer by 14% (SRR, 0.86; 95% CI, 0.77–0.96) (Fig. 3a).

Caffeinated coffee consumption lowered skin cancer incidence by 18% (SRR, 0.82; 95% CI, 0.71–
0.94), whereas decaffeinated coffee consumption had no association with skin cancer incidence
(SRR, 0.97; 95% CI, 0.86–1.10) (Fig. 3a). There was a greater decrease in skin cancer incidence
by 49% in men (SRR, 0.51; 95% CI, 0.20–1.29), compared to a 22% reduction in women (SRR,
0.78; 95% CI, 0.50–1.22) (Fig. 3b). A dose-response analysis showed a noticeable decreasing
trend in skin cancer incidence with an increase in coffee consumption: 7.8% reduction per daily
cup (Fig. 3c).

136

137 Breast cancer

Overall, our meta-analysis of 15 prospective studies^{14,23,29,30,38-48} found that coffee consumption slightly lowered breast cancer incidence (SRR, 0.95; 95% CI, 0.92–0.99) (**Fig. 4a**). Both caffeinated coffee consumption (SRR, 0.95; 95% CI, 0.90–1.01) and decaffeinated coffee consumption (SRR, 0.96; 95% CI, 0.89–1.04) had a decreasing trend in breast cancer risk (**Fig. 4a**). A dose-response analysis showed a decreasing trend in breast cancer incidence with an increase in coffee consumption: 1.2% reduction per daily cup (**Fig. 4b**).

144

145 **Pancreatic cancer**

Overall, our meta-analysis of eight prospective studies^{14,30,49-54} found that coffee consumption had 146 147 no significant association with pancreatic cancer incidence (SRR, 0.96; 95% CI, 0.84-1.09) (Fig. 148 5a). Caffeinated coffee consumption may protect against pancreatic cancer (SRR, 0.94; 95% CI, 149 0.59–1.48), whereas decaffeinated coffee consumption may increase pancreatic cancer risk 150 (SRR, 1.08; 95% CI, 0.77–1.50) (Fig. 5a). Coffee consumption may have a greater protective 151 effect in men (SRR, 0.83; 95% CI 0.62–1.12) than in women (SRR, 0.93; 95% CI 0.76–1.12) (Fig. 152 5b). A dose-response analysis showed a decreasing trend in pancreatic cancer incidence with an 153 increase in coffee consumption (Fig. 5c).

155 **Prostate cancer**

Our meta-analysis of eight prospective studies^{29,30,55-60} found that the overall SRR for prostate cancer with coffee consumption was 0.98 (95% CI, 0.94–1.02), indicating no significant association between coffee consumption and prostate cancer risk (**Fig. 6a**). Caffeinated (SRR, 0.98; 95% CI, 0.89–1.07) and decaffeinated coffee consumption (SRR, 0.98; 95% CI, 0.87–1.11) also had no association with prostate cancer risk (**Fig. 6a**). A dose-response analysis demonstrated no significant relationship between coffee consumption and prostate cancer risk (**Fig. 6b**).

163

164 Colorectal cancer

165 Overall, our meta-analysis of 11 prospective studies^{14,30,45,61-68} found that coffee consumption had 166 no association with colorectal cancer incidence (SRR, 0.99; 95% CI, 0.91-1.08) (Fig. 7a). 167 Intriguingly, decaffeinated coffee consumption had a decreasing trend in colorectal cancer 168 incidence (SRR, 0.88; 95% CI, 0.73-1.07), but caffeinated coffee consumption did not (SRR, 169 0.99; 95% CI, 0.86–1.14) (Fig. 7a). SRRs for male and female coffee drinkers were 1.10 (95% 170 Cl, 0.95–1.28) and 1.02 (95% Cl, 0.85–1.21), respectively (Fig. 7b). A dose-response analysis 171 showed no significant relationship between coffee consumption and colorectal cancer risk (Fig. 172 7c).

173

174 **Ovarian cancer**

Overall, our meta-analysis of nine prospective studies^{14,15,23,29,30,45,69-71} found that SRR for ovarian cancer in coffee drinkers was 1.00 (95% CI, 0.82–1.23), indicating no association between coffee consumption and ovarian cancer risk (**Fig. 8a**). The *I*² of 53.9% indicated moderate heterogeneity; the Park et al. study showed hazard ratio (HR) of 0.33 (95% CI, 0.17–0.65)¹⁴, whereas the Silvera et al. study showed HR of 1.62 (95% CI, 0.95–2.75)⁷¹. Although it was not statistically significant, caffeinated coffee consumption had an increasing trend in ovarian cancer risk (SRR, 1.13; 95%

- CI, 0.78–1.64), and decaffeinated coffee consumption had a decreasing trend (SRR, 0.89; 95%
 CI, 0.68–1.17) (Fig. 8a). A dose-response analysis demonstrated no significant relationship
 between coffee consumption and ovarian cancer risk (Fig. 8b).
- 184

185 Bladder cancer

Our meta-analysis of six prospective studies^{14,29,52,72-74}, including 8,012 bladder cancer cases 186 187 across the United States, Japan, Norway, and Sweden, found that SRR for bladder cancer in 188 coffee drinkers was 1.11 (95% CI, 0.98–1.26), demonstrating no significant association between 189 coffee consumption and bladder cancer risk (Fig. 9a). Only the Loftfield et al. study differentiated 190 between caffeinated and decaffeinated coffee consumption; HRs for caffeinated coffee and 191 decaffeinated coffee were 1.20 (95% CI, 1.06–1.35) and 1.18 (95% CI, 1.00–1.38), respectively, 192 when adjusted for smoking and other confounders⁷². Positive associations between coffee 193 consumption and bladder cancer risk were found among those who had ever smoked, but not in 194 those who had never smoked, suggesting that residual confounding from imperfect measurement 195 of smoking or unmeasured risk factors contributes to the observed positive associations⁷². SRRs 196 for male and female coffee drinkers were 1.08 (95% CI, 0.84–1.39) and 0.96 (95% CI, 0.71–1.29), 197 respectively (Fig. 9b). A dose-response analysis showed no significant relationship between 198 coffee consumption and bladder cancer risk (Fig. 9c).

199

200 Lung cancer

201 Our meta-analysis of five prospective studies^{14,29,45,75,76} included 12,725 cases of lung cancer and 202 found an overall SRR of 1.19 (95% CI, 1.07–1.34) for coffee drinkers, demonstrating a significant 203 positive association (**Fig. 10a**). Only the Guertin et al. study differentiated between caffeinated 204 and decaffeinated coffee consumption; HRs for caffeinated coffee and decaffeinated coffee were 205 1.18 (95% CI, 1.07–1.31) and 1.13 (95% CI, 1.00–1.29), respectively⁷⁵. Compared to SRR for 206 male coffee drinkers (SRR, 1.08; 95% CI, 0.90–1.29), SRR for female coffee drinkers was higher

- 207 (SRR, 1.48; 95% CI, 0.97–2.28) (Fig. 10b). This is due to the Lukic et al. study that found a
- 208 greater effect for heavy coffee drinkers (>7 cups per day)⁴⁵, which is a higher consumption than
- 209 in other studies. A dose-response analysis demonstrated an increasing trend in lung cancer
- 210 incidence with higher coffee consumption: 5.3% increase per daily cup (**Fig. 10c**).

212 **Discussion**

213

214 To investigate whether coffee prevents cancer, we systematically identified and meta-analyzed 215 63 high-guality prospective cohort studies from different geographical regions of the world, which 216 included 10,068,955 people in total. We excluded case-control studies, which may have recall 217 and selection biases. Unlike most prior meta-analyses, we comprehensively included 10 major 218 cancer types, which cover 59.9% of cancer incidences world-wide⁷⁷, and uniquely differentiated 219 between caffeinated and decaffeinated coffee consumption and between men and women. The 220 overall SRR for 10 major cancer types for high coffee consumption was 0.93 (95% Cl. 0.88–0.97). 221 demonstrating the cancer-preventive effects of coffee (Supplementary Fig. 2). Between-study 222 heterogeneity among included cohort studies was high ($l^2 = 65.7\%$, p < 0.001), and thus we 223 analyzed each cancer type separately. Our meta-analyses revealed that coffee consumption 224 reduced the risk of developing liver cancer (SRR, 0.62; 95% CI, 0.52–0.75), endometrial cancer 225 (SRR, 0.70; 95% CI, 0.61–0.80), skin cancer (SRR, 0.86; 95% CI, 0.77–0.96), and breast cancer 226 (SRR, 0.95; 95% CI, 0.92–0.99), whereas coffee consumption increased lung cancer incidence 227 (SRR, 1.19; 95% CI, 1.07–1.34) (Supplementary Fig. 3). There was no significant difference in 228 cancer-preventive effects of coffee between male and female coffee drinkers. The observed 229 positive association for coffee consumption with increased risk of lung cancer is likely due to the 230 residual confounding by tobacco smoking. Coffee drinkers were far more likely to smoke tobacco 231 than nondrinkers⁷⁵. Furthermore, the positive association between coffee consumption and risk of lung cancer was only observed in tobacco smokers, but not in nonsmokers^{78,79}. 232

233

One of the limitations of our meta-analyses is that, even after differentiating caffeinated and decaffeinated coffee consumption, between-study heterogeneity was significant in caffeinated coffee studies for endometrial cancer ($l^2 = 65.1\%$, p = 0.035), colorectal cancer ($l^2 = 51.2\%$, p =

237 0.105), and ovarian cancer ($l^2 = 70.3\%$, p = 0.018). This could be due to the inaccuracy of selfreported coffee consumption or changes in coffee intake after study recruitment⁸⁰. Also, 238 considerable heterogeneity exists in coffee cup size and caffeine content per serving⁸¹. Our meta-239 240 analyses included studies from many different countries, and there are different cultural norms for 241 standard size and brewing of coffee. The degree of coffee bean roasting alters the chemical composition of coffee⁸², and coffee brewing methods significantly affect caffeine content^{83,84}. 242 243 Furthermore, the effect of coffee consumption on inflammatory responses is variable in humans; 244 coffee consumption had pro-inflammatory effects in some individuals but anti-inflammatory effects in other individuals⁸⁵. 245

246

247 Our meta-analyses found that caffeinated coffee, but not decaffeinated coffee, prevents liver 248 cancer (SRR, 0.54; 95% CI, 0.39-0.74) and skin cancer (SRR, 0.82; 95% CI, 0.71-0.94), 249 highlighting the significant role of caffeine in cancer prevention (Supplementary Fig. 3). Coffee 250 contains many bioactive compounds, but previous mouse studies clearly showed that caffeine is 251 the active compound that prevents UV-induced skin carcinogenesis^{9,10}. Caffeine inhibits multiple 252 enzymes, including the ATR kinase that senses UV-induced DNA damage⁸⁶. Genetic inhibition of 253 ATR in skin augments UV-induced apoptosis and suppresses UV-induced skin carcinogenesis, 254 suggesting that ATR inhibition is the relevant mechanism for cancer-preventive effects of 255 caffeine⁸⁷. The augmentation of UV-induced apoptosis by caffeine or ATR inhibition may be 256 beneficial to eliminate DNA-damaged cells that are precancerous, leading to the suppression of UV-induced skin cancer development^{88,89}. Additionally, caffeine induces phase II detoxifying and 257 258 antioxidant enzymes, thereby inhibiting carcinogenesis⁹⁰.

259

Our meta-analyses also found that decaffeinated coffee prevents endometrial cancer (SRR, 0.73;
95% CI, 0.58–0.93), although caffeinated coffee consumption has a stronger preventive effect
(SRR, 0.61; 95% CI, 0.44–0.84) (Supplementary Fig. 3). This indicates that active compounds

263 in coffee other than caffeine also play a key role in endometrial cancer prevention. Coffee contains 264 caffeine, chlorogenic acid, diterpenes (mainly cafestol and kahweol), and trigonelline, which affect 265 many different biological processes⁸. Coffee consumption induces glutathione-S-transferases 266 (GSTs), which inactivate a broad variety of environmental and dietary toxins⁹¹. GST induction by 267 unfiltered and paper filtered coffees, differing in cafestol and kahweol contents, was identical, 268 indicating that the diterpene concentrations were not responsible for GST induction⁹¹. Instead, 269 chlorogenic acid, which is an abundant polyphenol in coffee, stimulates NRF2, a transcription 270 factor that induces antioxidant defense including GST induction⁹²⁻⁹⁴. Activation of NRF2 271 decreases reactive oxygen species (ROS) levels and prevents ROS-induced mutations, thereby inhibiting carcinogenesis^{88,95}. Cafestol and kahweol have anti-angiogenic properties, which may 272 273 contribute to cancer prevention⁹⁶.

274

275 Due to the popularity of coffee and high frequency of cancer, coffee consumption has a large 276 impact on saving healthcare cost. Based on the estimated numbers of new cancer cases in one 277 year (liver 41,210; uterine corpus 66,200; melanoma 97,610; nonmelanoma skin cancer 278 5,434,193 [equal incidence rates for basal cell carcinoma and squamous cell carcinoma])^{1,97}, per-279 patient annualized average cancer-attributable costs for initial care (liver \$62.776; uterus \$39,040; 280 melanoma \$8,537; basal cell carcinoma \$1,456; squamous cell carcinoma \$1,326)⁹⁸⁻¹⁰⁰, and per-281 cup risk changes from our meta-analyses (liver -9.9%; endometrial -7.4%; skin -7.8%), we 282 estimate that total \$1.1 billion of healthcare cost could be saved annually in the United States if 283 Americans drink one additional cup of coffee every day. Furthermore, a previous large prospective 284 cohort study showed that coffee consumption reduced all-cause mortality, highlighting the health 285 benefits of coffee⁷. However, coffee consumption was not inversely associated with deaths due 286 to cancer⁷. This may be because the greatest number of cancer deaths are from cancers of the 287 lung, prostate, colorectum, and pancreas in men and of the lung, breast, colorectum, pancreas,

- and ovary in women¹. All these cancers were not prevented by coffee consumption in our meta-
- analyses, except for a minimal preventive effect found for breast cancer.
- 290
- 291 Taken together, our meta-analyses of high-quality prospective cohort studies on 10 major cancer
- 292 types from different countries revealed that coffee consumption, in particular caffeinated coffee,
- 293 prevents the incidence of liver, endometrial, and skin cancers in a dose-dependent manner.
- 294 Further investigations are needed to clarify why some types of cancer are prevented by coffee
- 295 consumption while others are not.
- 296

297 Methods

298

299 Literature search

300 We utilized electronic databases PubMed. Scopus, and Embase to comprehensively search for 301 peer-reviewed prospective cohort studies published up to July 2020 without a specific start date. 302 To create a comprehensive list of potential studies, we used the following search terms for all 303 three databases: caffeine, coffee, economics, consumption, drinking, skin cancer, breast cancer, 304 lung cancer, prostate cancer, colorectal cancer, non-Hodgkin lymphoma, renal cell cancer, 305 endometrial cancer, childhood leukemia, pancreatic cancer, thyroid cancer, hepatocellular 306 cancer, ovarian cancer, bladder cancer, epidemiology, prevalence, incidence, risk, humans, and 307 English language. We also utilized reference lists from compiled studies to get a comprehensive 308 list of cohort studies. Furthermore, we utilized the "Similar articles" function in PubMed to include 309 other related articles. Search results were uploaded to Rayyan QCRI system to detect and delete 310 duplications among the three databases.

311

312 Inclusion and exclusion criteria

313 When compiling a list of potential cohort studies to systematically review, we only included articles 314 that fulfilled the following inclusion criteria: full-length, published, peer-reviewed articles written in 315 English with a prospective cohort study design that included relative risks (or hazard ratios) with 316 95% confidence intervals (CIs), dose-response relationships between coffee consumption and 317 cancer risk, human subjects, and coffee beverage. Studies were excluded if they are a case-318 control or retrospective cohort study, do not discuss coffee or caffeine, or do not have a dose-319 response categorization. In the instance that multiple studies analyzed the same cohort, we 320 included the most updated study.

322 After a comprehensive list was compiled, we performed a full-text screening to further eliminate 323 any unrelated studies that did not fulfill our inclusion criteria. To assess the quality of prospective 324 cohort studies we selected, we utilized the Newcastle-Ottawa Scale (NOS) for nonrandomized 325 studies in meta-analyses¹⁰¹. Studies that had a NOS score less than 5 were excluded. After our 326 comprehensive screening, we had to eliminate our analysis for non-Hodgkin lymphoma, renal cell 327 cancer, childhood leukemia, and thyroid cancer because of limited data availability from 328 prospective cohort studies. As a result, the following 10 cancer types were included in the final 329 analysis: liver, endometrial, skin, breast, pancreatic, prostate, colorectal, ovarian, bladder, and 330 lung.

331

Data extraction

From the final list of high-quality prospective cohort studies, we extracted the following data: publication year, cancer type, country, region, study year, total sample size, relative risk (or hazard ratio) with 95% CI for each dose of coffee consumption, coffee type (caffeinated and decaffeinated), and sex (men and women). Only multivariable adjusted data were extracted to eliminate potential confounding factors.

338

339 Data analysis

340 We performed random-effects meta-analyses using Stata 18 (StataCorp LLC) to integrate the 341 results of included studies for the highest coffee consumption. For each cancer type (liver, 342 endometrial, skin, breast, pancreatic, prostate, colorectal, ovarian, bladder, and lung), coffee type 343 (caffeinated and decaffeinated), and sex (men and women), summary relative risks (SRRs) and 344 95% Cls were calculated using the DerSimonian–Laird random-effects model, estimating the 345 between-study variance. Hazard ratio is an estimate of relative risk¹⁰², and thus we treated hazard 346 ratio as relative risk to calculate SRR. To quantify the impact of heterogeneity in a meta-analysis, 347 we calculated l^2 , which ranges from 0% to 100%¹⁰³.

348

349 For dose-response analyses of coffee consumption and cancer risk, we performed linear 350 regression using Prism 9 (GraphPad Software). Coffee data (without distinguishing between 351 caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, 352 were included because the majority of coffee drinkers consume caffeinated coffee rather than 353 decaffeinated coffee¹⁰⁴. Due to the varying nature of how each cohort study reported the amount 354 of coffee consumption, we categorized varying amounts of coffee consumption into low and high 355 consumption groups. We defined low consumption to be less than three cups of coffee per day 356 and high consumption to be greater than or equal to three cups per day. After this grouping, we 357 used relative risk (or hazard ratio) from each study and calculated a SRR for each consumption 358 group. The x-value for our linear regression model represented the mean daily cup of coffee 359 consumption with its 95% CI. The y-value represented SRR with reference set at 1. We excluded 360 the studies that reported nonquantifiable coffee consumption from our linear regression analysis. 361 362

³⁶² Publication bias in our meta-analysis was evaluated using the Egger's test, Begg's test, and a ³⁶³ funnel plot after applying the trim-and-fill method¹⁰⁵⁻¹⁰⁷.

365 **References**

- Siegel, R.L., Miller, K.D., Wagle, N.S. & Jemal, A. Cancer statistics, 2023. *CA Cancer J Clin* 73, 17-48 (2023).
- Ames, B.N., Gold, L.S. & Willett, W.C. The causes and prevention of cancer. *Proc Natl Acad Sci U S A* 92, 5258-5265 (1995).
- 370 3. Loftfield, E. et al. Coffee Drinking Is Widespread in the United States, but Usual Intake
- 371 Varies by Key Demographic and Lifestyle Factors. *J Nutr* **146**, 1762-1768 (2016).
- 4. Arab, L. Epidemiologic evidence on coffee and cancer. *Nutr Cancer* **62**, 271-283 (2010).
- 5. Huxley, R. et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident
- 374 type 2 diabetes mellitus: a systematic review with meta-analysis. *Arch Intern Med* **169**,
- 375 2053-2063 (2009).
- Modi, A.A. et al. Increased caffeine consumption is associated with reduced hepatic
 fibrosis. *Hepatology* **51**, 201-209 (2010).
- Freedman, N.D., Park, Y., Abnet, C.C., Hollenbeck, A.R. & Sinha, R. Association of
 coffee drinking with total and cause-specific mortality. *N Engl J Med* 366, 1891-1904
 (2012).
- 381 8. Nuhu, A.A. Bioactive micronutrients in coffee: recent analytical approaches for
 382 characterization and quantification. *ISRN Nutr* **2014**, 384230 (2014).
- 383 9. Huang, M.T. et al. Effects of tea, decaffeinated tea, and caffeine on UVB light-induced
- 384 complete carcinogenesis in SKH-1 mice: demonstration of caffeine as a biologically
- 385 important constituent of tea. *Cancer Res* **57**, 2623-2629 (1997).
- Conney, A.H., Lu, Y.P., Lou, Y.R., Kawasumi, M. & Nghiem, P. Mechanisms of Caffeine Induced Inhibition of UVB Carcinogenesis. *Front Oncol* 3, 144 (2013).
- 38811.Abel, E.L. et al. Daily coffee consumption and prevalence of nonmelanoma skin cancer
- 389 in Caucasian women. *Eur J Cancer Prev* **16**, 446-452 (2007).

- Song, F., Qureshi, A.A. & Han, J. Increased caffeine intake is associated with reduced
 risk of basal cell carcinoma of the skin. *Cancer Res* **72**, 3282-3289 (2012).
- 392 13. Loftfield, E. et al. Coffee drinking and cutaneous melanoma risk in the NIH-AARP diet
- 393 and health study. *J Natl Cancer Inst* **107**(2015).
- 14. Park, S.Y. et al. Prospective Study of Coffee Consumption and Cancer Incidence in
- 395 Non-White Populations. *Cancer Epidemiol Biomarkers Prev* **27**, 928-935 (2018).
- 15. Lueth, N.A., Anderson, K.E., Harnack, L.J., Fulkerson, J.A. & Robien, K. Coffee and
- 397 caffeine intake and the risk of ovarian cancer: the Iowa Women's Health Study. *Cancer*
- 398 *Causes Control* **19**, 1365-1372 (2008).
- Song, J.W. & Chung, K.C. Observational studies: cohort and case-control studies. *Plast Reconstr Surg* 126, 2234-2242 (2010).
- 401 17. Bamia, C. et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular
- 402 carcinoma in a European population: multicentre, prospective cohort study. *Int J Cancer*403 **136**, 1899-1908 (2015).
- 404 18. Petrick, J.L. et al. Coffee Consumption and Risk of Hepatocellular Carcinoma and
- 405 Intrahepatic Cholangiocarcinoma by Sex: The Liver Cancer Pooling Project. *Cancer*
- 406 *Epidemiol Biomarkers Prev* **24**, 1398-1406 (2015).
- 407 19. Setiawan, V.W. et al. Association of coffee intake with reduced incidence of liver cancer
 408 and death from chronic liver disease in the US multiethnic cohort. *Gastroenterology* 148,
 409 118-125 (2015).
- 410 20. Tamura, T. et al. Coffee, Green Tea, and Caffeine Intake and Liver Cancer Risk: A
- 411 Prospective Cohort Study. *Nutr Cancer* **70**, 1210-1216 (2018).
- 412 21. Inoue, M., Yoshimi, I., Sobue, T., Tsugane, S. & Group, J.S. Influence of coffee drinking
- 413 on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. *J Natl*

414 *Cancer Inst* **97**, 293-300 (2005).

415	22.	Shimazu, T. et al. Coffee consumption and the risk of primary liver cancer: pooled
416		analysis of two prospective studies in Japan. Int J Cancer 116, 150-154 (2005).
417	23.	Arthur, R., Kirsh, V.A. & Rohan, T.E. Associations of coffee, tea and caffeine intake with
418		risk of breast, endometrial and ovarian cancer among Canadian women. Cancer
419		<i>Epidemiol</i> 56 , 75-82 (2018).
420	24.	Giri, A. et al. Caffeinated coffee, decaffeinated coffee and endometrial cancer risk: a
421		prospective cohort study among US postmenopausal women. Nutrients 3, 937-950
422		(2011).
423	25.	Gunter, M.J. et al. A prospective investigation of coffee drinking and endometrial cancer
424		incidence. Int J Cancer 131, E530-536 (2012).
425	26.	Uccella, S. et al. Intake of coffee, caffeine and other methylxanthines and risk of Type I
426		vs Type II endometrial cancer. Br J Cancer 109, 1908-1913 (2013).
427	27.	Friberg, E., Orsini, N., Mantzoros, C.S. & Wolk, A. Coffee drinking and risk of
428		endometrial cancera population-based cohort study. Int J Cancer 125, 2413-2417
429		(2009).
430	28.	Gavrilyuk, O. et al. High coffee consumption and different brewing methods in relation to
431		postmenopausal endometrial cancer risk in the Norwegian women and cancer study: a
432		population-based prospective study. BMC Womens Health 14, 48 (2014).
433	29.	Hashibe, M. et al. Coffee, tea, caffeine intake, and the risk of cancer in the PLCO cohort.
434		<i>Br J Cancer</i> 113 , 809-816 (2015).
435	30.	Nilsson, L.M., Johansson, I., Lenner, P., Lindahl, B. & Van Guelpen, B. Consumption of
436		filtered and boiled coffee and the risk of incident cancer: a prospective cohort study.
437		Cancer Causes Control 21 , 1533-1544 (2010).
438	31.	Shimazu, T. et al. Coffee consumption and risk of endometrial cancer: a prospective
439		study in Japan. Int J Cancer 123, 2406-2410 (2008).

- 440 32. Weiderpass, E. et al. Endometrial cancer in relation to coffee, tea, and caffeine
- 441 consumption: a prospective cohort study among middle-aged women in Sweden. *Nutr*

442 *Cancer* **66**, 1132-1143 (2014).

- 443 33. Yang, T.O., Crowe, F., Cairns, B.J., Reeves, G.K. & Beral, V. Tea and coffee and risk of
 444 endometrial cancer: cohort study and meta-analysis. *Am J Clin Nutr* **101**, 570-578
- 445 (2015).
- 446 34. Caini, S. et al. Coffee, tea and melanoma risk: findings from the European Prospective
 447 Investigation into Cancer and Nutrition. *Int J Cancer* 140, 2246-2255 (2017).
- 448 35. Miura, K., Hughes, M.C., Green, A.C. & van der Pols, J.C. Caffeine intake and risk of
- basal cell and squamous cell carcinomas of the skin in an 11-year prospective study.
- 450 *Eur J Nutr* **53**, 511-520 (2014).
- 451 36. Wu, S. et al. Caffeine Intake, Coffee Consumption, and Risk of Cutaneous Malignant
 452 Melanoma. *Epidemiology* 26, 898-908 (2015).
- 453 37. Oh, C.C., Jin, A., Yuan, J.M. & Koh, W.P. Coffee, tea, caffeine, and risk of
- 454 nonmelanoma skin cancer in a Chinese population: The Singapore Chinese Health
- 455 Study. J Am Acad Dermatol **81**, 395-402 (2019).
- 456 38. Bhoo-Pathy, N. et al. Coffee and tea consumption and risk of pre- and postmenopausal
- 457 breast cancer in the European Prospective Investigation into Cancer and Nutrition
- 458 (EPIC) cohort study. *Breast Cancer Res* **17**, 15 (2015).
- 459 39. Boggs, D.A. et al. Tea and coffee intake in relation to risk of breast cancer in the Black
 460 Women's Health Study. *Cancer Causes Control* 21, 1941-1948 (2010).
- 461 40. Ganmaa, D. et al. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up. *Int*462 *J Cancer* 122, 2071-2076 (2008).
- 463 41. Gierach, G.L. et al. Coffee intake and breast cancer risk in the NIH-AARP diet and
 464 health study cohort. *Int J Cancer* **131**, 452-460 (2012).

- 465 42. Ishitani, K., Lin, J., Manson, J.E., Buring, J.E. & Zhang, S.M. Caffeine consumption and
- 466 the risk of breast cancer in a large prospective cohort of women. Arch Intern Med **168**,

467 2022-2031 (2008).

- 468 43. Bhoo Pathy, N. et al. Coffee and tea intake and risk of breast cancer. *Breast Cancer Res*469 *Treat* 121, 461-467 (2010).
- 470 44. Larsson, S.C., Bergkvist, L. & Wolk, A. Coffee and black tea consumption and risk of
- 471 breast cancer by estrogen and progesterone receptor status in a Swedish cohort.

472 *Cancer Causes Control* **20**, 2039-2044 (2009).

- 473 45. Lukic, M. et al. Coffee consumption and the risk of cancer in the Norwegian Women and
 474 Cancer (NOWAC) Study. *Eur J Epidemiol* **31**, 905-916 (2016).
- 475 46. Michels, K.B., Holmberg, L., Bergkvist, L. & Wolk, A. Coffee, tea, and caffeine
- 476 consumption and breast cancer incidence in a cohort of Swedish women. *Ann Epidemiol*
- 477 **12**, 21-26 (2002).
- 478 47. Oh, J.K. et al. Prospective study of breast cancer in relation to coffee, tea and caffeine in
 479 Sweden. *Int J Cancer* 137, 1979-1989 (2015).
- 480 48. Vatten, L.J., Solvoll, K. & Loken, E.B. Coffee consumption and the risk of breast cancer.
- 481 A prospective study of 14,593 Norwegian women. *Br J Cancer* **62**, 267-270 (1990).
- 482 49. Bhoo-Pathy, N. et al. Intake of coffee, decaffeinated coffee, or tea does not affect risk for
- 483 pancreatic cancer: results from the European Prospective Investigation into Nutrition and
- 484 Cancer Study. *Clin Gastroenterol Hepatol* **11**, 1486-1492 (2013).
- 485 50. Michaud, D.S., Giovannucci, E., Willett, W.C., Colditz, G.A. & Fuchs, C.S. Coffee and
- 486 alcohol consumption and the risk of pancreatic cancer in two prospective United States
- 487 cohorts. Cancer Epidemiol Biomarkers Prev 10, 429-437 (2001).
- 488 51. Bidel, S. et al. Coffee consumption and risk of gastric and pancreatic cancer--a
- 489 prospective cohort study. *Int J Cancer* **132**, 1651-1659 (2013).

490	52.	Lukic, M., Nilsson, L.M., Skeie, G., Lindahl, B. & Braaten, T. Coffee consumption and
491		risk of rare cancers in Scandinavian countries. Eur J Epidemiol 33, 287-302 (2018).
492	53.	Luo, J. et al. Green tea and coffee intake and risk of pancreatic cancer in a large-scale,
493		population-based cohort study in Japan (JPHC study). Eur J Cancer Prev 16, 542-548
494		(2007).
495	54.	Zhou, C.D. et al. Coffee and pancreatic cancer risk among never-smokers in the UK
496		prospective Million Women Study. Int J Cancer 145, 1484-1492 (2019).
497	55.	Sen, A. et al. Coffee and tea consumption and risk of prostate cancer in the European
498		Prospective Investigation into Cancer and Nutrition. Int J Cancer 144, 240-250 (2019).
499	56.	Wilson, K.M. et al. Coffee consumption and prostate cancer risk and progression in the
500		Health Professionals Follow-up Study. J Natl Cancer Inst 103, 876-884 (2011).
501	57.	Bosire, C. et al. Coffee consumption and the risk of overall and fatal prostate cancer in
502		the NIH-AARP Diet and Health Study. Cancer Causes Control 24, 1527-1534 (2013).
503	58.	Ellison, L.F. Tea and other beverage consumption and prostate cancer risk: a Canadian
504		retrospective cohort study. Eur J Cancer Prev 9, 125-130 (2000).
505	59.	Li, Q. et al. Coffee consumption and the risk of prostate cancer: the Ohsaki Cohort
506		Study. Br J Cancer 108, 2381-2389 (2013).
507	60.	Shafique, K. et al. Coffee consumption and prostate cancer risk: further evidence for
508		inverse relationship. <i>Nutr J</i> 11 , 42 (2012).
509	61.	Dominianni, C., Huang, W.Y., Berndt, S., Hayes, R.B. & Ahn, J. Prospective study of the
510		relationship between coffee and tea with colorectal cancer risk: the PLCO Cancer
511		Screening Trial. Br J Cancer 109, 1352-1359 (2013).
512	62.	Groessl, E.J. et al. Coffee Consumption and the Incidence of Colorectal Cancer in
513		Women. J Cancer Epidemiol 2016, 6918431 (2016).
514	63.	Sinha, R. et al. Caffeinated and decaffeinated coffee and tea intakes and risk of
515		colorectal cancer in a large prospective study. Am J Clin Nutr 96, 374-381 (2012).

516	64.	Um, C.Y. et al. Coffee consumption and risk of colorectal cancer in the Cancer
517		Prevention Study-II Nutrition Cohort. Cancer Epidemiol 67, 101730 (2020).
518	65.	Lee, K.J. et al. Coffee consumption and risk of colorectal cancer in a population-based
519		prospective cohort of Japanese men and women. Int J Cancer 121, 1312-1318 (2007).
520	66.	Naganuma, T. et al. Coffee consumption and the risk of colorectal cancer: a prospective
521		cohort study in Japan. Int J Cancer 120 , 1542-1547 (2007).
522	67.	Peterson, S. et al. Coffee intake and risk of colorectal cancer among Chinese in
523		Singapore: the Singapore Chinese Health Study. Nutr Cancer 62, 21-29 (2010).
524	68.	Yamada, H. et al. Coffee consumption and risk of colorectal cancer: the Japan
525		Collaborative Cohort Study. J Epidemiol 24, 370-378 (2014).
526	69.	Braem, M.G. et al. Coffee and tea consumption and the risk of ovarian cancer: a
527		prospective cohort study and updated meta-analysis. Am J Clin Nutr 95, 1172-1181
528		(2012).
529	70.	Tworoger, S.S., Gertig, D.M., Gates, M.A., Hecht, J.L. & Hankinson, S.E. Caffeine,
529 530	70.	Tworoger, S.S., Gertig, D.M., Gates, M.A., Hecht, J.L. & Hankinson, S.E. Caffeine, alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112 , 1169-
	70.	
530	70. 71.	alcohol, smoking, and the risk of incident epithelial ovarian cancer. Cancer 112 , 1169-
530 531		alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112 , 1169-1177 (2008).
530 531 532		alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112 , 1169- 1177 (2008). Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. & Rohan, T.E. Intake of coffee and tea
530531532533	71.	 alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112, 1169-1177 (2008). Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. & Rohan, T.E. Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. <i>Nutr Cancer</i> 58, 22-27 (2007).
 530 531 532 533 534 	71.	 alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112, 1169-1177 (2008). Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. & Rohan, T.E. Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. <i>Nutr Cancer</i> 58, 22-27 (2007). Loftfield, E., Freedman, N.D., Inoue-Choi, M., Graubard, B.I. & Sinha, R. A Prospective
 530 531 532 533 534 535 	71.	 alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112, 1169-1177 (2008). Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. & Rohan, T.E. Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. <i>Nutr Cancer</i> 58, 22-27 (2007). Loftfield, E., Freedman, N.D., Inoue-Choi, M., Graubard, B.I. & Sinha, R. A Prospective Investigation of Coffee Drinking and Bladder Cancer Incidence in the United States.
 530 531 532 533 534 535 536 	71. 72.	 alcohol, smoking, and the risk of incident epithelial ovarian cancer. <i>Cancer</i> 112, 1169-1177 (2008). Silvera, S.A., Jain, M., Howe, G.R., Miller, A.B. & Rohan, T.E. Intake of coffee and tea and risk of ovarian cancer: a prospective cohort study. <i>Nutr Cancer</i> 58, 22-27 (2007). Loftfield, E., Freedman, N.D., Inoue-Choi, M., Graubard, B.I. & Sinha, R. A Prospective Investigation of Coffee Drinking and Bladder Cancer Incidence in the United States. <i>Epidemiology</i> 28, 685-693 (2017).

- 540 74. Sugiyama, K. et al. The association between coffee consumption and bladder cancer
- 541 incidence in a pooled analysis of the Miyagi Cohort Study and Ohsaki Cohort Study. *Eur*

542 *J Cancer Prev* **26**, 125-130 (2017).

- 543 75. Guertin, K.A. et al. Coffee consumption and incidence of lung cancer in the NIH-AARP
- 544 Diet and Health Study. *Int J Epidemiol* **45**, 929-939 (2016).
- 545 76. Narita, S. et al. Coffee Consumption and Lung Cancer Risk: The Japan Public Health

546 Center-Based Prospective Study. *J Epidemiol* **28**, 207-213 (2018).

- 547 77. World Cancer Research Fund International. Cancer Trends: Worldwide Cancer Data;
- 548 2022. Available from: <u>https://www.wcrf.org/cancer-trends/worldwide-cancer-data/</u>.
- 549 78. Xie, Y. et al. Coffee consumption and the risk of lung cancer: an updated meta-analysis

of epidemiological studies. *Eur J Clin Nutr* **70**, 199-206 (2016).

- 551 79. Galarraga, V. & Boffetta, P. Coffee Drinking and Risk of Lung Cancer-A Meta-Analysis.
 552 *Cancer Epidemiol Biomarkers Prev* 25, 951-957 (2016).
- 553 80. Pauwels, E.K.J. & Volterrani, D. Coffee Consumption and Cancer Risk: An Assessment
- of the Health Implications Based on Recent Knowledge. *Med Princ Pract* **30**, 401-411
- 555 (2021).
- 556 81. Bracken, M.B. et al. Heterogeneity in assessing self-reports of caffeine exposure:
- 557 implications for studies of health effects. *Epidemiology* **13**, 165-171 (2002).
- Ludwig, I.A. et al. Variations in caffeine and chlorogenic acid contents of coffees: what
 are we drinking? *Food Funct* 5, 1718-1726 (2014).
- 560 83. Severini, C. et al. How the variance of some extraction variables may affect the quality of 561 espresso coffees served in coffee shops. *J Sci Food Agric* **96**, 3023-3031 (2016).
- 562 84. Angeloni, G. et al. What kind of coffee do you drink? An investigation on effects of eight
- 563 different extraction methods. *Food Res Int* **116**, 1327-1335 (2019).
- 564 85. Muqaku, B. et al. Coffee consumption modulates inflammatory processes in an
- 565 individual fashion. *Mol Nutr Food Res* **60**, 2529-2541 (2016).

- Sarkaria, J.N. et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing
 agent, caffeine. *Cancer Res* 59, 4375-4382 (1999).
- 568 87. Kawasumi, M. et al. Protection from UV-induced skin carcinogenesis by genetic
- 569 inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase. *Proc Natl Acad Sci*
- 570 *U S A* **108**, 13716-13721 (2011).
- 571 88. Lee, J.W., Ratnakumar, K., Hung, K.F., Rokunohe, D. & Kawasumi, M. Deciphering UV-
- 572 induced DNA Damage Responses to Prevent and Treat Skin Cancer. *Photochem*
- 573 Photobiol **96**, 478-499 (2020).
- 574 89. Heffernan, T.P. et al. ATR-Chk1 pathway inhibition promotes apoptosis after UV
- 575 treatment in primary human keratinocytes: potential basis for the UV protective effects of

576 caffeine. *J Invest Dermatol* **129**, 1805-1815 (2009).

- 577 90. Tao, K.S. et al. The multifaceted mechanisms for coffee's anti-tumorigenic effect on liver.
 578 *Med Hypotheses* **71**, 730-736 (2008).
- 579 91. Steinkellner, H. et al. Coffee consumption induces GSTP in plasma and protects
- 580 lymphocytes against (+/-)-anti-benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide induced
- 581 DNA-damage: results of controlled human intervention trials. *Mutat Res* **591**, 264-275 582 (2005).
- 583 92. Feng, R. et al. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of
 584 phase 2 detoxifying enzyme activity by chlorogenic acid. *J Biol Chem* 280, 27888-27895
 585 (2005).
- 586 93. Ramos, S. Cancer chemoprevention and chemotherapy: dietary polyphenols and
- 587 signalling pathways. *Mol Nutr Food Res* **52**, 507-526 (2008).
- 588 94. Kolb, H., Kempf, K. & Martin, S. Health Effects of Coffee: Mechanism Unraveled?
 589 *Nutrients* 12(2020).
- 590 95. Misik, M. et al. Impact of paper filtered coffee on oxidative DNA-damage: results of a
 591 clinical trial. *Mutat Res* 692, 42-48 (2010).

- 592 96. Moeenfard, M. et al. Anti-Angiogenic Properties of Cafestol and Kahweol Palmitate
 593 Diterpene Esters. *J Cell Biochem* **117**, 2748-2756 (2016).
- 594 97. Rogers, H.W., Weinstock, M.A., Feldman, S.R. & Coldiron, B.M. Incidence Estimate of
- 595 Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012.
- 596 *JAMA Dermatol* **151**, 1081-1086 (2015).
- 597 98. National Cancer Institute. Cancer Trends Progress Report: Financial Burden of Cancer
- 598 Care; 2022. Available from: <u>https://progressreport.cancer.gov/after/economic_burden</u>.
- 599 99. Mariotto, A.B., Enewold, L., Zhao, J., Zeruto, C.A. & Yabroff, K.R. Medical Care Costs
- 600 Associated with Cancer Survivorship in the United States. *Cancer Epidemiol Biomarkers*
- 601 *Prev* **29**, 1304-1312 (2020).
- 100. Yoon, J., Phibbs, C.S., Chow, A., Pomerantz, H. & Weinstock, M.A. Costs of
- 603 Keratinocyte Carcinoma (Nonmelanoma Skin Cancer) and Actinic Keratosis Treatment
- in the Veterans Health Administration. *Dermatol Surg* **42**, 1041-1047 (2016).
- 605 101. Wells, G.A. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of
- 606 nonrandomised studies in meta-analyses; 2022. Available from:
- 607 <u>https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.</u>
- Spruance, S.L., Reid, J.E., Grace, M. & Samore, M. Hazard ratio in clinical trials. *Antimicrob Agents Chemother* 48, 2787-2792 (2004).
- 610 103. Higgins, J.P. & Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat Med*611 **21**, 1539-1558 (2002).
- 612 104. Kubo Shlonsky, A., Klatsky, A.L. & Armstrong, M.A. Traits of persons who drink
- 613 decaffeinated coffee. *Ann Epidemiol* **13**, 273-279 (2003).
- 614 105. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected
 615 by a simple, graphical test. *BMJ* **315**, 629-634 (1997).
- 616 106. Begg, C.B. & Mazumdar, M. Operating characteristics of a rank correlation test for
- 617 publication bias. *Biometrics* **50**, 1088-1101 (1994).

- 618 107. Duval, S. & Tweedie, R. Trim and fill: A simple funnel-plot-based method of testing and
- 619 adjusting for publication bias in meta-analysis. *Biometrics* **56**, 455-463 (2000).

621 Author contributions


- 622 All authors contributed intellectual input and assistance to this study.
- 623 T.N.N. and M.K. designed the research.
- 624 T.N.N. and D.K.E. conducted literature search and data extraction.
- 625 T.N.N. and M.K. analyzed and visualized data.
- 626 T.N.N., O.S.C., D.K.E., and M.K. interpreted data and wrote the manuscript.
- 627 M.K. supervised the research.
- 628

629 **Competing interests**

- 630 The authors declare no competing interest.
- 631

632 Data availability

633 All data are presented within this paper and in the accompanying Supplementary Information.



b

Author	Year		RR (95% CI)	% Weight	Highest Consumption
Men					
Inoue et al.	2005		0.27 (0.09, 0.87)	2.74	≥5 Cups/Day
Park et al.	2018		0.58 (0.35, 0.95)	14.16	≥4 Cups/Day
Shimazu et al.	2005		0.64 (0.37, 1.12)	11.51	≥1 Cup/Day
Heterogeneity: I ²	= 0.00%, p = 0.400	+	0.56 (0.39, 0.80)		
Women					
Inoue et al.	2005			3.13	3-4 Cups/Day
Park et al.	2018		0.57 (0.26, 1.25)	5.73	≥4 Cups/Day
Shimazu et al.	2005		- 0.54 (0.14, 2.07)	1.95	≥1 Cup/Day
Heterogeneity: I ²	= 0.00%, p = 0.773		0.64 (0.36, 1.14)		
Men and Womer	ı				
Bamia et al.	2015		0.38 (0.22, 0.66)	11.70	Quintile 5
Petrick et al.	2015		0.71 (0.50, 1.01)	28.56	>3 Cups/Day
Setiawan et al.	2015		0.59 (0.35, 0.99)	13.06	≥4 Cups/Day
Tamura et al.	2018		0.40 (0.20, 0.79)	7.48	≥2 Times/Day
Heterogeneity: I ²	= 35.10%, p = 0.202	•	0.54 (0.39, 0.74)		
Overall		•	0.57 (0.47, 0.69)		
Heterogeneity: I2	= 0.00%, p = 0.621				
		0.125 0.25 0.5 1 2	2		
		Relative Risk			

Fig. 1: Coffee consumption and hepatocellular carcinoma risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.

c Dose-response analysis of coffee consumption and hepatocellular carcinoma risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.





Fig. 2: Coffee consumption and endometrial cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Dose-response analysis of coffee consumption and endometrial cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.



b




Fig. 3: Coffee consumption and skin cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.


c Dose-response analysis of coffee consumption and skin cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.

а						b	
Author	Year		RR (95% CI)	% Weight	Highest Consumption		Breast
Caffeinated Coffee		i	. ,	0		- 1.5	Y = -0.0122X + 1.01
Arthur et al.	2018		1.04 (0.71, 1.53)	0.83	>4 Cups/Day	1.0	-
Bhoo-Pathy et al.	2015		0.91 (0.83, 1.00)	14.11	High Intake		-
Boggs et al.	2010		1.03 (0.77, 1.39)	1.40	≥4 Cups/Day		1
Ganmaa et al.	2008		0.92 (0.82, 1.03)	9.42	≥4 Cups/Day	풇 1.0	
Gierach et al.	2012		0.98 (0.90, 1.08)	14.74	≥4 Cups/Day	Ř	- ^{' ± '}
Ishitani et al.	2008		1.08 (0.89, 1.30)	3.41	≥4 Cups/Day	tive	1
Heterogeneity: $I^2 = 0$.	00%, p = 0.577		0.95 (0.90, 1.01)			Relative Risk 0.0	_
Decaffeinated Coffe	e					- 0.5	-
Arthur et al.	2018		0.93 (0.62, 1.38)	0.77	>2 Cups/Day		1
Bhoo-Pathy et al.	2015		0.95 (0.83, 1.10)	6.18	High Intake		-
Boggs et al.	2010		0.82 (0.61, 1.11)	1.37	≥2 Cups/Day	0.0	
Ganmaa et al.	2008		1.03 (0.81, 1.31)	2.12	≥4 Cups/Day		0 1 2 3 4 5 6
Gierach et al.	2012		1.00 (0.88, 1.15)	6.84	≥4 Cups/Day		Coffee Consumption (Cups/Day)
Ishitani et al.	2008		0.93 (0.78, 1.10)	4.15	≥2 Cups/Day		(Cups/Day)
Heterogeneity: $I^2 = 0$.	00%, p = 0.859	+	0.96 (0.89, 1.04)				
Coffee							
Bhoo Pathy et al.	2010		0.94 (0.72, 1.24)	1.66	>5 Cups/Day		
Hashibe et al.	2015		0.97 (0.87, 1.08)	10.48	≥2 Cups/Day		
Larsson et al.	2009		1.02 (0.87, 1.20)	4.74	≥4 Cups/Day		
Lukic et al.	2016		0.87 (0.71, 1.06)	3.05	>7 Cups/Day		
Michels et al.	2002		0.94 (0.75, 1.28)	1.71	≥4 Cups/Day		
Nilsson et al.	2010		0.92 (0.68, 1.25)	1.32	≥4 Occasions/Day		
Oh et al.	2015	- -	0.81 (0.70, 0.94)	5.64	≥5 Cups/Day		
Park et al.	2018	++∎	1.08 (0.93, 1.25)	5.60	≥4 Cups/Day		
Vatten et al.	1990		0.80 (0.48, 1.35)	0.46	≥7 Cups/Day		
Heterogeneity: I ² = 15	5.78%, p = 0.302	+	0.95 (0.88, 1.01)				
Overall Heterogeneity: I ² = 0.	00%, p = 0.759	•	0.95 (0.92, 0.99)				
		0.5 1	2				
		Relative Risk					

Fig. 4: Coffee consumption and breast cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Dose-response analysis of coffee consumption and breast cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.



b

Author	Year		RR (95% CI)	% Weight	Highest Consumption		
Men			1				
Bidel et al.	2013	-			0.80 (0.30, 1.95)	2.24	≥10 Cups/Day
Lukic et al.	2018			-	0.72 (0.37, 1.42)	4.35	≥4 Cups/Day
Luo et al.	2007	-			0.60 (0.31, 1.14)	4.66	≥3 Cups/Day
Park et al.	2018		i	_	1.02 (0.67, 1.55)	11.18	≥4 Cups/Day
Heterogeneity: I ² =	0.00%, p = 0.559		-		0.83 (0.62, 1.12)		
Women							
Bidel et al.	2013				0.71 (0.14, 3.63)	0.74	≥10 Cups/Day
Lukic et al.	2018				0.85 (0.62, 1.17)	19.50	≥4 Cups/Day
Luo et al.	2007			<u> </u>	1.30 (0.51, 3.34)	2.21	≥3 Cups/Day
Park et al.	2018				1.20 (0.76, 1.88)	9.59	≥4 Cups/Day
Zhou et al.	2019				0.87 (0.64, 1.18)	21.01	≥5 Cups/Day
Heterogeneity: I ² =	0.00%, p = 0.681		+		0.93 (0.76, 1.12)		
Men and Women							
Bhoo-Pathy et al.	2013		-	-	1.07 (0.78, 1.47)	19.58	High Intake
Michaud et al.	2001		-	-	0.62 (0.27, 1.43)	2.83	>3 Cups/Day
Nilsson et al.	2010			•	-1.50 (0.57, 3.92)	2.12	≥4 Occasions/Day
Heterogeneity: I ² =	3.07%, p = 0.356		+	•	1.03 (0.76, 1.39)		
Overall					0.93 (0.81, 1.07)		
Heterogeneity: I ² =	0.00%, p = 0.758						
		0.125 0.25	0.5 1	2	4		
		1	Relative Risk				

Fig. 5: Coffee consumption and pancreatic cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.

c Dose-response analysis of coffee consumption and pancreatic cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.





Fig. 6: Coffee consumption and prostate cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Dose-response analysis of coffee consumption and prostate cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.






Fig. 7: Coffee consumption and colorectal cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.
 b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.

c Dose-response analysis of coffee consumption and colorectal cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.





Fig. 8: Coffee consumption and ovarian cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Dose-response analysis of coffee consumption and ovarian cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.




					0/ 14/- 1-1-1	Highest
Author	Year		P	RR (95% CI)	% Weight	Consumption
Men						
Kurahashi et al.	2009			—1.37 (0.75, 2.51)	5.34	≥3 Cups/Day
Loftfield et al.	2017		; 	1.25 (1.09, 1.43)	26.27	≥4 Cups/Day
Lukic et al.	2018			- 1.23 (0.78, 1.95)	8.30	≥4 Cups/Day
Park et al.	2018		-	0.89 (0.56, 1.43)	8.01	≥4 Cups/Day
Sugiyama et al.	2017	-		0.57 (0.31, 1.07)	5.12	≥3 Cups/Day
Heterogeneity: I ² =	= 47.60%, p = 0.106			1.08 (0.84, 1.39)		
Women						
Kurahashi et al.	2009			0.55 (0.23, 1.33)	2.76	≥1 Cup/Day
Loftfield et al.	2017			0.97 (0.74, 1.26)	16.49	≥4 Cups/Day
Lukic et al.	2018		- <u>i</u> -•-		6.28	≥4 Cups/Day
Park et al.	2018			- 0.84 (0.34, 2.08)	2.61	≥4 Cups/Day
Sugiyama et al.	2017			- 0.44 (0.10, 1.97)	1.01	≥3 Cups/Day
Heterogeneity: I2 =	= 18.81%, p = 0.295			0.96 (0.71, 1.29)		
Men and Women			1			
Hashibe et al.	2015			1.08 (0.85, 1.39)	17.80	≥2 Cups/Day
Heterogeneity: $I^2 = .\%$, p = .				1.08 (0.85, 1.39)		
Overall				1.06 (0.91, 1.23)		
Heterogeneity: I ² =	= 33.79%, p = 0.128		1			
		0.125 0.25	0.5 1	2		
		Rel	lative Risk			
				2		

Fig. 9: Coffee consumption and bladder cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated), but not caffeinated coffee data or decaffeinated coffee data, were included.

c Dose-response analysis of coffee consumption and bladder cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.



b




Fig. 10: Coffee consumption and lung cancer risk.

a Meta-analyses classified by coffee type. "Coffee" data did not distinguish between caffeinated and decaffeinated coffee consumption.

b Meta-analyses classified by sex. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.

c Dose-response analysis of coffee consumption and lung cancer risk. Mean coffee consumption (cups per day) with 95% confidence interval and summary relative risk with 95% confidence interval for reference, low, and high consumption groups are shown. Coffee data (without distinguishing between caffeinated and decaffeinated) and caffeinated coffee data, but not decaffeinated coffee data, were included.